Drawing for SANTARIS PHARMA A/S

USPTO serial 79090386

SANTARIS PHARMA A/S

Reviewed by CopyMark Law Group

Reg. 4069179Status 404
Filing date
Status date
Registration date
Dec 13, 2011
Examiner
PILARO, MARK F
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SANTARIS PHARMA A/S?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

M. David Galin

M. David Galin Renner, Otto, Boisselle & Sklar LLP1621 Euclid Avenue, 19th FloorCleveland, OH 44115UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and veterinary preparations, namely, preparations comprising nucleotides, nucleotide analogs, oligonucleotides and oligonucleotide analogs for treating of diseases, disorders and afflictions except for preparations directed to gastrointestinal diseases and disordersSECTION 71 - CANCELLED—
042Scientific and technological services, namely, research and design in the field of nucleotides, nucleotide analogs, oligonucleotides and oligonucleotide analogs except for preparations directed to gastrointestinal diseases and disorders; development of medical and biomedical products and preparations, namely, in the field of nucleotides, nucleotide analogs, oligonucleotides and oligonucleotide analogs except for preparations directed to gastrointestinal diseases and disorders; biomedical and biotechnological analysis of RNA expression and protein expression, and biomedical and biotechnological research; biochemical and molecular biological analysis of RNA expression and protein expression; scientific, biotechnological and biomedical consultancy, namely, in the field of disease related RNA expression and protein expression; in vivo and in vitro pre-clinical testing of potential pharmaceutical, medical and veterinary preparations, methods and products except for preparations directed to gastrointestinal diseases and disorders; analysis of therapeutic effects of chemical, pharmaceutical, medical and veterinary preparations, namely, analysis in the field of medicine and veterinary medicine except for preparations directed to gastrointestinal diseases and disordersSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 27, 2021DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Jun 27, 2021DETHDEATH OF INTERNATIONAL REGISTRATION—
May 17, 2019INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Mar 23, 2019INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Mar 23, 2019INPCINVALIDATION PROCESSED—
Mar 20, 2019INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jul 20, 2018C71TCANCELLED SECTION 71—
Dec 13, 2016REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Nov 7, 2014NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jun 11, 2012FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
May 23, 2012FICSFINAL DISPOSITION NOTICE SENT TO IB—
May 23, 2012FIMPFINAL DISPOSITION PROCESSED—
Apr 17, 2012GPNXNOTIFICATION PROCESSED BY IB—
Mar 13, 2012FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Dec 13, 2011R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 27, 2011NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 27, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 7, 2011OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 7, 2011OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Aug 24, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 23, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 23, 2011XAECEXAMINER'S AMENDMENT ENTERED—
Aug 23, 2011GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 23, 2011GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 23, 2011CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 13, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 13, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 30, 2011ALIEASSIGNED TO LIE—
Jun 20, 2011TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 22, 2011RFNTREFUSAL PROCESSED BY IB—
Jan 4, 2011RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jan 4, 2011RFRRREFUSAL PROCESSED BY MPU—
Jan 3, 2011MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 31, 2010RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 30, 2010CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 28, 2010DOCKASSIGNED TO EXAMINER—
Dec 28, 2010NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 23, 2010REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance